Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Oct 7, 2011


Gail Page has stepped down as chairman of the board at Vermillion. Page will still remain CEO. In her place, the company elected James Burns as chairman.

Burns has been a director of the board since 2005, and is the president and CEO of AssureRx. Previously he was president and CEO of EntreMed.

Waters has recognized the University of Minnesota's Mass Spectrometry Laboratory as a Waters Center of Innovation, citing in particular the work of the facility's head Joseph Dalluge.

Dalluge is the thirteenth researcher recognized by the program. His research focuses on diagnostic marker development for cystic fibrosis and other diseases, using LC-MS instruments including Waters' Aqcuity UPLC/TQD and Synapt G2 for metabolite profiling, biomarker discovery, and chemical characterization of biological systems.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.